Retatrutide Clinical Escalation Schedule (TRIUMPH Trials)
Retatrutide (LY3437943) is an experimental triple-agonist targeting GLP-1, GIP, and glucagon receptors. Published clinical trial protocols (including Phase 2 and Phase 3 TRIUMPH programs) evaluated a structured 4-week step-up escalation ladder to build metabolic tolerance:
| Protocol Phase | Trial Timeline | Weekly Dose | 10 mg Vial (2 mL BAC) | Primary Clinical Objective |
|---|---|---|---|---|
| Initiation / Step 1 | Weeks 1–4 | 2.0 mg / week | 40 units (0.40 mL) | Establish GI receptor tolerance |
| Step 2 Escalation | Weeks 5–8 | 4.0 mg / week | 80 units (0.80 mL) | Appetite reduction & metabolic onset |
| Step 3 Escalation | Weeks 9–12 | 6.0 mg or 9.0 mg / week | Split or larger volume | Active weight reduction phase |
| Maintenance Phase | Weeks 13+ | Up to 12.0 mg / week | Full therapeutic target | Long-term glycemic & adipose regulation |
Reconstitution Quick Reference: 10 mg vs 15 mg Vials
Because research peptide vials must be dissolved with bacteriostatic water (0.9% benzyl alcohol), the volume of water dictates the concentration and the exact units required on standard U-100 (100 units = 1.0 mL) syringes:
| Vial Size | BAC Water Added | Resulting Concentration | 1.0 mg Dose | 2.0 mg Dose | 4.0 mg Dose |
|---|---|---|---|---|---|
| 10 mg Vial | 1.0 mL | 10.0 mg/mL (100 mcg/unit) | 10 units (0.10 mL) | 20 units (0.20 mL) | 40 units (0.40 mL) |
| 10 mg Vial | 2.0 mL | 5.0 mg/mL (50 mcg/unit) | 20 units (0.20 mL) | 40 units (0.40 mL) | 80 units (0.80 mL) |
| 15 mg Vial | 3.0 mL | 5.0 mg/mL (50 mcg/unit) | 20 units (0.20 mL) | 40 units (0.40 mL) | 80 units (0.80 mL) |
Split-Dosing Considerations (Twice Weekly)
In observational community research reports, approximately 31% of researchers split their weekly dose into two injections (e.g., Monday morning and Thursday evening). Splitting the dose halves the volume drawn per administration and helps avoid high peak concentrations that can cause transient nausea.
Laboratory Research and Educational Notice
Retatrutide is an investigational compound not approved by the US FDA, EMA, or Health Canada for commercial medical prescription outside authorized clinical trials. This calculator is provided strictly as an educational and mathematical reference for scientific laboratory research. Always follow certified compounding protocols.